CLSD RSI Chart
Last 7 days
4.8%
Last 30 days
4.0%
Last 90 days
4.8%
Trailing 12 Months
29.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 3.1M | 4.8M | 6.5M | 8.2M |
2022 | 22.5M | 15.5M | 8.4M | 1.3M |
2021 | 13.3M | 18.7M | 24.2M | 29.6M |
2020 | 6.2M | 6.5M | 9.8M | 7.9M |
2019 | 565.8K | 1.1M | 1.6M | 2.2M |
2018 | 0 | 0 | 0 | 30.0K |
2017 | 476.3K | 432.5K | 388.8K | 345.0K |
2016 | 0 | 0 | 0 | 520.0K |
2015 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 18, 2024 | gibney anthony s | bought | 121,277 | 1.3 | 93,290 | - |
Apr 17, 2024 | gibney anthony s | bought | 8,387 | 1.25 | 6,710 | - |
Mar 20, 2024 | chong ngai hang victor | bought | 48,000 | 1.6 | 30,000 | chief medical officer |
Feb 07, 2024 | whitmore bradford t | bought | 599,999 | 1.35 | 444,444 | - |
Jan 19, 2024 | deignan charles a. | sold | -16,512 | 1.28 | -12,900 | chief financial officer |
Jan 19, 2024 | lasezkay george m | sold | -22,860 | 1.27 | -18,000 | ceo |
Nov 01, 2023 | whitmore bradford t | bought | 47,901 | 0.7442 | 64,366 | - |
Oct 31, 2023 | whitmore bradford t | bought | 51,537 | 0.7278 | 70,812 | - |
Oct 30, 2023 | whitmore bradford t | bought | 411 | 0.685 | 600 | - |
Oct 03, 2023 | hutson nancy j | bought | 8,600 | 0.86 | 10,000 | - |
Which funds bought or sold CLSD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 270,360 | 270,360 | -% |
May 15, 2024 | MARSHALL WACE, LLP | new | - | 104,749 | 104,749 | -% |
May 15, 2024 | FIRST MANHATTAN CO. LLC. | unchanged | - | 63,000 | 267,750 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 401 | 7,324 | 8,641 | -% |
May 15, 2024 | Steward Partners Investment Advisory, LLC | sold off | -100 | -12,870 | - | -% |
May 15, 2024 | Cubist Systematic Strategies, LLC | new | - | 37,592 | 37,592 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | new | - | 6,052,680 | 6,052,680 | 0.08% |
May 15, 2024 | Northeast Financial Consultants Inc | unchanged | - | 33,480 | 142,290 | 0.01% |
May 15, 2024 | Mariner, LLC | unchanged | - | 6,822 | 28,994 | -% |
May 15, 2024 | Curi RMB Capital, LLC | new | - | 38,250 | 38,250 | -% |
Unveiling Clearside Biomedical Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Clearside Biomedical Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Clearside Biomedical Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -100.0% | - | 6,345 | 859 | 1,018 | 674 | 330 | 266 | 384 | 13,036 | 25,687 | 3,074 | 780 | 396 | 11.00 | 3,432 | 354 | 4,097 | 1,942 | 141 | 45.00 | 45.00 |
Operating Expenses | -8.9% | 8,439 | 9,260 | 7,913 | 8,288 | 7,609 | 8,400 | 6,990 | 8,221 | 7,993 | 6,980 | 7,963 | 6,876 | 8,383 | 7,121 | 5,864 | 5,911 | 6,933 | 4,955 | 6,509 | 5,662 | 15,351 |
S&GA Expenses | -100.0% | - | 2,947 | 2,637 | 3,127 | 3,158 | 3,169 | 2,353 | 2,791 | 3,457 | 3,140 | 2,816 | 2,816 | 2,893 | 2,649 | 2,374 | 2,611 | 3,122 | 3,650 | 3,781 | 5,004 | 4,384 |
R&D Expenses | -11.1% | 5,615 | 6,313 | 5,134 | 4,948 | 4,451 | 5,027 | 4,637 | 5,430 | 4,536 | 3,840 | 5,147 | 4,060 | 5,490 | 4,472 | 3,490 | 3,300 | 3,811 | 1,305 | 2,728 | 658 | 10,967 |
Net Income | -143.4% | -11,763 | -4,832 | -9,267 | -9,106 | -9,280 | -9,663 | -7,827 | -7,813 | -7,644 | 18,709 | -4,887 | -6,095 | -7,351 | -7,112 | -2,433 | -5,754 | -2,911 | -3,096 | -6,536 | -5,734 | -15,404 |
Net Income Margin | -7.6% | -4.25* | -3.95* | -5.74* | -7.51* | -11.33* | -24.83* | -0.55* | -0.11* | 0.00* | 0.01* | -1.05* | -1.23* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -2208.8% | -7,908 | 375 | -6,520 | -6,436 | -7,331 | -5,698 | -6,341 | -5,443 | 3,871 | 5,054 | -3,278 | -6,950 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 18.0% | 40.00 | 34.00 | 34.00 | 39.00 | 45.00 | 51.00 | 56.00 | 31.00 | 36.00 | 43.00 | 27.00 | 29.00 | 28.00 | 19.00 | 17.00 | 18.00 | 25.00 | 27.00 | 26.00 | 30.00 | 38.00 |
Current Assets | 19.9% | 36.00 | 30.00 | 31.00 | 36.00 | 43.00 | 49.00 | 55.00 | 30.00 | 35.00 | 42.00 | 27.00 | 28.00 | 27.00 | 18.00 | 16.00 | 16.00 | 24.00 | 25.00 | 24.00 | 28.00 | 35.00 |
Cash Equivalents | 22.4% | 35.00 | 29.00 | 29.00 | 35.00 | 41.00 | 48.00 | 53.00 | 29.00 | 34.00 | 30.00 | 25.00 | 26.00 | 26.00 | 17.00 | 15.00 | 15.00 | 21.00 | 23.00 | 23.00 | 26.00 | 33.00 |
Net PPE | 6.6% | 3.00 | 3.00 | 3.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | 24.1% | 62.00 | 50.00 | 47.00 | 44.00 | 42.00 | 41.00 | 37.00 | 5.00 | 4.00 | 5.00 | 10.00 | 9.00 | 11.00 | 11.00 | 9.00 | 10.00 | 15.00 | 16.00 | 16.00 | 17.00 | 21.00 |
Current Liabilities | -12.7% | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 9.00 | 9.00 | 10.00 | 10.00 | 8.00 | 9.00 | 14.00 | 11.00 | 11.00 | 8.00 | 12.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | - | 4.00 | 4.00 | 8.00 | 9.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 0.00 | 5.00 | 1.00 | 6.00 | 2.00 | 1.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | - | 4.00 | 4.00 | 8.00 | 9.00 |
Shareholder's Equity | -37.1% | -21.81 | -15.91 | - | - | 3.00 | 11.00 | 19.00 | 25.00 | 32.00 | 38.00 | 18.00 | 19.00 | 17.00 | 9.00 | 8.00 | 7.00 | 10.00 | 11.00 | 10.00 | 13.00 | 16.00 |
Retained Earnings | -3.7% | -332 | -320 | -316 | -306 | -297 | -288 | -278 | -270 | -263 | -255 | -274 | -269 | -263 | -255 | -248 | -246 | -240 | -237 | -234 | -228 | -222 |
Additional Paid-In Capital | 1.9% | 311 | 305 | 303 | 302 | 300 | 299 | 297 | 296 | 295 | 293 | 292 | 289 | 280 | 265 | 257 | 254 | 251 | 249 | 244 | 241 | 238 |
Shares Outstanding | 18.9% | 75.00 | 63.00 | 62.00 | 62.00 | 61.00 | 61.00 | 60.00 | 60.00 | 60.00 | 58.00 | 59.00 | 58.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 64.00 | - | - | - | 80.00 | - | - | - | 228 | - | - | - | 66.00 | - | - | - | 33.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -1686.1% | -7,851 | 495 | -6,075 | -5,339 | -7,216 | -5,607 | -6,186 | -5,443 | 3,871 | 5,054 | -3,278 | -6,950 | -5,559 | -4,436 | -2,661 | -3,220 | -2,803 | 1,689 | -6,047 | -10,057 | -12,653 |
Share Based Compensation | 3.5% | 1,062 | 1,026 | 1,074 | 1,061 | 1,041 | 1,149 | 1,074 | 1,354 | 1,307 | 1,253 | 1,316 | 1,331 | 1,154 | 867 | 841 | 891 | 1,001 | 1,139 | 970 | 1,256 | 1,247 |
Cashflow From Investing | 52.5% | -57.00 | -120 | -445 | -1,097 | -115 | -91.00 | -155 | - | - | - | - | - | - | - | -110 | 110 | -55.00 | - | - | 1,993 | 30,932 |
Cashflow From Financing | 5680.9% | 14,343 | -257 | 317 | 22.00 | 332 | 575 | 30,689 | 4.00 | 65.00 | 165 | 2,081 | 7,117 | 14,419 | 6,884 | -463 | 253 | 1,193 | -1,645 | 2,424 | 1,288 | 6,628 |
Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
License and other revenue (includes $75 from a related party for the three months ended March 31, 2024) | $ 230 | $ 4 |
Type of Revenue [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember |
Operating expenses: | ||
Research and development (includes $256 to a related party for the three months ended March 31, 2024) | $ 5,615 | $ 4,451 |
General and administrative | 2,824 | 3,158 |
Total operating expenses | 8,439 | 7,609 |
Loss from operations | (8,209) | (7,605) |
Interest income | 348 | 492 |
Other expense | (1,499) | 0 |
Non-cash interest expense on liability related to the sales of future royalties | (2,403) | (2,167) |
Net loss | $ (11,763) | $ (9,280) |
Net loss per share of common stock - basic | $ (0.17) | $ (0.15) |
Net loss per share of common stock - diluted | $ (0.17) | $ (0.15) |
Weighted average shares outstanding - basic | 69,853,227 | 61,169,486 |
Weighted average shares outstanding - diluted | 69,853,227 | 61,169,486 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 35,355 | $ 28,920 |
Accounts receivable | 0 | 170 |
Prepaid expenses | 567 | 722 |
Other current assets | 193 | 311 |
Total current assets | 36,115 | 30,123 |
Property and equipment, net | 3,194 | 2,996 |
Operating lease right-of-use asset | 803 | 869 |
Other assets | 30 | 30 |
Total assets | 40,142 | 34,018 |
Current liabilities: | ||
Accounts payable (includes $17 and $331 to a related party as of March 31, 2024 and December 31, 2023, respectively) | 1,363 | 2,205 |
Accrued liabilities (includes $198 and $215 to a related party as of March 31, 2024 and December 31, 2023, respectively) | 4,070 | 4,169 |
Current portion of operating lease liabilities | 367 | 364 |
Deferred revenue | 150 | 75 |
Total current liabilities | 5,950 | 6,813 |
Liability related to the sales of future royalties, net | 44,391 | 41,988 |
Warrant liabilities | 11,039 | 0 |
Operating lease liabilities | 572 | 649 |
Other non-current liabilities | 0 | 480 |
Total liabilities | 61,952 | 49,930 |
Commitments and contingencies | ||
Stockholders' (deficit) equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 74,731,139 and 62,850,841 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 74 | 63 |
Additional paid-in capital | 310,802 | 304,948 |
Accumulated deficit | (332,686) | (320,923) |
Total stockholders' (deficit) equity | (21,810) | (15,912) |
Total liabilities and stockholders' (deficit) equity | $ 40,142 | $ 34,018 |